摘要
目的:观察多西紫杉醇(TXT)对晚期乳腺癌的疗效、安全性、剂量限制性毒性(DLT)和最大耐受剂量(MTD)。方法:TXT按剂量递增分为65、75、85mg.m-2。第1天静脉滴注,剂量递增至出现DLT。结果:15例患者中,完全缓解1例,部分缓解5例,稳定4例,进展5例。TXT的DLT为中性粒细胞减少,MTD为85mg.m-2。结论:TXT75mg.m-2治疗晚期乳腺癌疗效显著,耐受性良好。
OBJECTIVE： To observe the clinical efficacy, safety, the maximal tolerated dose （MTD） and dose- limiting toxicity （DLT） of docetaxel （TXT） in the treatment advanced breast cancer. METHODS： Doeetaxel was given by drip infusion in escalating doses from the initial dose of 65 mg·m^-2 to 75 mg ·m^-2 and 85 mg·m^-2 until the appearance of DLT. RESULTS： Among the 15 cases, i case with CR, 5 PR, 4 SD, and 5 PD. The DLT of TXT was neutropenia, and its MTD was 85 mg·m^-2. CONCLUSION： Docetaxel （at a dose of 75 mg ·m^-2） showed remarkable efficacy and good tolerance in patietns with advanced breast cancer.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第29期2286-2287,共2页
China Pharmacy
